Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers

Protocol
12-153
Full Title
Myeloablative Unrelated Donor Cord Blood Transplantation with T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients with High Risk Hematological Malignancies
Phase
II
Disease Status
Relapsed/Refractory
Purpose

Stem cell transplantation is often used in patients with hematologic cancers who have had chemotherapy to help rebuild their blood-forming and immune systems. But not every patient has a stem cell donor who is a close enough genetic match.

In these cases, doctors may use umbilical cord blood, which is a rich source of stem cells. Cord blood collections from two newborns (a “double-unit” transplant) can be used to increase the number of cord blood cells patients receive, further enhancing their recovery. But even in this case, recovery can take a long time.

The purpose of this study is to see if recovery during the first few weeks after transplantation can be enhanced by using double-unit cord blood transplantation followed by an infusion of blood stem cells from a close relative in patients with hematological cancers that are advanced or at high risk of relapse. To prevent a potential complication of transplantation known as graft-versus-host disease (where the white blood cells from the donor attack the recipient’s tissues), T cells will be removed from the relative’s stem cells before giving them to the patient. This is known as “T-cell depletion.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of an acute leukemia with a high risk of relapse, chronic leukemia that has progressed or reached blast crisis, advanced myelodysplastic syndrome, or aggressive lymphoma.
  • Patients must have a close relative who can serve as a donor of stem cells.
  • This study is open to patients aged 2 to 70.

For more information and to inquire about eligibility for this study, please contact Dr. Juliet Barker at 212-639-3468.

Disease(s)
Blood & Marrow Stem Cell Transplantation
Blood and Marrow Transplantation: Transplantation
Hematology: Myelodysplastic Syndrome
Leukemia
Leukemia: Chronic Myelocytic Leukemia
Leukemia: Myelodysplastic Syndrome
Lymphoma
Lymphoma: Non-Hodgkin's Lymphoma
Locations